Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Diabetic Kidney Disease: Combo Therapy Targets Zombie CellsKey Points Researchers from Mayo Clinic.
Heart Attack Recovery: Single Injection May Heal the HeartKey Points Researchers have developed a.
Fragmentome Technology Detects Early Liver FibrosisKey Points at a Glance AI-based.
CTNNB1 Syndrome Study Explores Beta-Catenin DefectsKey Takeaways Researchers in Spain are.
Tuberculosis Breakthrough with Experimental AntibioticsKey Takeaways Experimental antibiotics disrupt a.
National Healthy Longevity Trial Receives Federal SupportKey Summary Up to $38 million.
Red Blood Cells Improve Glucose Tolerance Under HypoxiaKey Takeaways for Clinicians Chronic hypoxia.
Nanoplastics in Brain Tissue and Neurological RiskKey Takeaways for HCPs Nanoplastics are.
AI Predicts Chronic GVHD Risk After Stem Cell TransplantKey Takeaways A new AI-driven tool,.
Red Meat Consumption Linked to Higher Diabetes OddsKey Takeaways Higher intake of total,.
Leave a Comment